Francischetti Ivo M B, Toomer Kevin, Zhang Yifan, Jani Jayesh, Siddiqui Zishan, Brotman Daniel J, Hooper Jody E, Kickler Thomas S
Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, United States.
Department of Biostatistics, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, United States.
EClinicalMedicine. 2021 Sep;39:101069. doi: 10.1016/j.eclinm.2021.101069. Epub 2021 Aug 6.
SARS-CoV-2 infection is associated with thrombotic and microvascular complications. The cause of coagulopathy in the disease is incompletely understood.
A single-center cross-sectional study including 66 adult COVID-19 patients (40 moderate, 26 severe disease), and 9 controls, performed between 04/2020 and 10/2020. Markers of coagulation, endothelial cell function [angiopoietin-1,-2, P-selectin, von Willebrand Factor Antigen (WF:Ag), von Willebrand Factor Ristocetin Cofactor, ADAMTS13, thrombomodulin, soluble Endothelial cell Protein C Receptor (sEPCR), Tissue Factor Pathway Inhibitor], neutrophil activation (elastase, citrullinated histones) and fibrinolysis (tissue-type plasminogen activator, plasminogen activator inhibitor-1) were evaluated using ELISA. Tissue Factor (TF) was estimated by antithrombin-FVIIa complex (AT/FVIIa) and microparticles-TF (MP-TF). We correlated each marker and determined its association with severity. Expression of pulmonary TF, thrombomodulin and EPCR was determined by immunohistochemistry in 9 autopsies.
Comorbidities were frequent in both groups, with older age associated with severe disease. All patients were on prophylactic anticoagulants. Three patients (4.5%) developed pulmonary embolism. Mortality was 7.5%. Patients presented with mild alterations in the coagulogram (compensated state). Biomarkers of endothelial cell, neutrophil activation and fibrinolysis were elevated in severe moderate disease; AT/FVIIa and MP-TF levels were higher in severe patients. Logistic regression revealed an association of -dimers, angiopoietin-1, vWF:Ag, thrombomodulin, white blood cells, absolute neutrophil count (ANC) and hemoglobin levels with severity, with ANC and vWF:Ag identified as independent factors. Notably, postmortem specimens demonstrated epithelial expression of TF in the lung of fatal COVID-19 cases with loss of thrombomodulin staining, implying in a shift towards a procoagulant state.
Coagulation dysregulation has multifactorial etiology in SARS-Cov-2 infection. Upregulation of pulmonary TF with loss of thrombomodulin emerge as a potential link to immunothrombosis, and therapeutic targets in the disease.
John Hopkins University School of Medicine.
严重急性呼吸综合征冠状病毒2(SARS-CoV-2)感染与血栓形成和微血管并发症相关。该疾病中凝血病的病因尚不完全清楚。
一项单中心横断面研究,于2020年4月至2020年10月期间纳入66例成年新型冠状病毒肺炎(COVID-19)患者(40例中度、26例重度)和9例对照。采用酶联免疫吸附测定(ELISA)评估凝血指标、内皮细胞功能标志物[血管生成素-1、-2、P-选择素、血管性血友病因子抗原(WF:Ag)、血管性血友病因子瑞斯托霉素辅因子、含血小板解聚蛋白和金属蛋白酶13(ADAMTS13)、血栓调节蛋白、可溶性内皮细胞蛋白C受体(sEPCR)、组织因子途径抑制物]、中性粒细胞活化指标(弹性蛋白酶、瓜氨酸化组蛋白)和纤维蛋白溶解指标(组织型纤溶酶原激活物、纤溶酶原激活物抑制剂-1)。通过抗凝血酶-凝血因子VIIa复合物(AT/FVIIa)和微粒-组织因子(MP-TF)评估组织因子(TF)。我们对每个指标进行相关性分析,并确定其与疾病严重程度的关联。通过免疫组织化学法在9例尸检中测定肺组织中TF、血栓调节蛋白和EPCR的表达。
两组患者合并症均较为常见,年龄较大与疾病严重程度相关。所有患者均接受预防性抗凝治疗。3例患者(4.5%)发生肺栓塞。死亡率为7.5%。患者凝血图出现轻度改变(代偿状态)。重度和中度疾病患者的内皮细胞、中性粒细胞活化和纤维蛋白溶解生物标志物升高;重度患者的AT/FVIIa和MP-TF水平更高。逻辑回归分析显示,D-二聚体、血管生成素-1、血管性血友病因子抗原、血栓调节蛋白、白细胞、绝对中性粒细胞计数(ANC)和血红蛋白水平与疾病严重程度相关,其中ANC和血管性血友病因子抗原被确定为独立因素。值得注意的是,尸检标本显示,致命COVID-19病例的肺组织中TF在上皮细胞表达,血栓调节蛋白染色缺失,这意味着向促凝状态转变。
SARS-CoV-2感染中凝血功能失调具有多因素病因。肺组织中TF上调且血栓调节蛋白缺失是免疫性血栓形成的潜在环节,也是该疾病的治疗靶点。
约翰·霍普金斯大学医学院。